Showing results (71-80 of 120) with videos related to
Sort By:
Pageof 12
Diabetology International|August 5, 2024
Impact of inpatient management of hyperglycemia on peripheral T cell markers in patients with type 2 diabetesTomohisa Kunii, Isao Usui, Teruo Jojima, et al.Journal of Medical Case Reports|April 21, 2019
Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case reportTomohisa Kunii, Toshie Iijima, Teruo Jojima, et al.Endocrine Journal|March 7, 2022
Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intoleranceTeruo Jojima, Toshimitsu Shinzawa, Eriko Ohira, et al.Atherosclerosis|April 27, 2017
Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient miceTeruo Jojima, Kohsuke Uchida, Kazumi Akimoto, et al.Postgraduate Medicine|April 25, 2024
High serum levels of CCL11/Eotaxin-1 are associated with diabetic sensorimotor polyneuropathy and peripheral nerve function but not with cardiac autonomic neuropathy in people with type 2 diabetesYoshimasa Aso, Toshie Iijima, Teruo Jojima, et al.Diabetology International|January 13, 2023
Relationship between reduced heart rate variability and increased arterial stiffness evaluated by the cardio-ankle vascular index in people with type 2 diabetesMasato Kase, Toshie Iijima, Takafumi Niitani, et al.The American Journal of Cardiology|August 19, 2007
High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery diseaseTeruo Inoue, Norihiko Kotooka, Toshifumi Morooka, et al.Journal of Diabetes Investigation|December 17, 2025
Evaluation of the effectiveness and safety of ONO-2910 for the treatment of diabetic polyneuropathy: An early Phase IIa, multicenter, randomized, placebo-controlled, double-blind study in Japanese patientsYukiko Onishi, Takeshi Osonoi, Norio Takahashi, et al.International Journal of Cardiology|February 8, 2021
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterolTeruo Jojima, Shintaro Sakurai, Sho Wakamatsu, et al.Saudi Medical Journal|February 12, 2013
Oxidative stress and antioxidative potency are closely associated with diabetic retinopathy and nephropathy in patients with type 2 diabetesRika Naruse, Mariko Suetsugu, Tomoko Terasawa, et al.Pageof 12